Top Health News Briefs: Low-Cost Ozempic, FDA's Blindsight Tag, and More

The latest health news includes Sen. Sanders advocating for affordable Ozempic, Neuralink's FDA 'breakthrough' for Blindsight, and various updates on significant medications and policies, including 23andMe's board resignations, an IVF bill failure, and a study predicting a surge in antibiotic-resistant deaths. Also featured are updates on climate impacts on child health and regulatory actions by Express Scripts.

The latest health news underscores significant developments. U.S. Senator Bernie Sanders confirmed major generic pharmaceutical companies could provide a copycat version of Novo Nordisk's diabetes drug Ozempic for under $100 a month. This move could significantly reduce costs for patients.

Additionally, Elon Musk's Neuralink received a 'breakthrough device' designation from the FDA for its Blindsight implant aimed at restoring vision. This tag helps expedite the development and review of innovative medical devices.

Meanwhile, Danish pharmaceutical giant Novo Nordisk expects Ozempic will be part of Medicare's 2027 price negotiations, as allowed by the Inflation Reduction Act. This effort could further reduce costs for millions of Americans.

(With inputs from agencies.)